We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-1.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$67.6M
AUM Growth
-$6.2M
Cap. Flow
-$3.41M
Cap. Flow %
-5.05%
Top 10 Hldgs %
57.93%
Holding
76
New
1
Increased
16
Reduced
1
Closed
13

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$259K
2
SRPT icon
Sarepta Therapeutics
SRPT
+$255K
3
EXAS
Exact Sciences
EXAS
+$246K
4
NKTR icon
Nektar Therapeutics
NKTR
+$73.7K
5
LGND icon
Ligand Pharmaceuticals
LGND
+$43.2K

Top Sells

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$506K
2
CLLS
Cellectis
CLLS
+$409K
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$408K
4
RUBY
Rubius Therapeutics, Inc
RUBY
+$391K
5
WVE icon
Wave Life Sciences
WVE
+$377K

Sector Composition

Rank Sector Weight
1 Healthcare 58.79%
2 Miscellaneous 41.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
26
DELISTED
Blueprint Medicines
BPMC
$640K 0.95%
6,780
– –
GTHX
27
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$639K 0.95%
20,844
– –
GWPH
28
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$633K 0.94%
3,674
– –
EPZM
29
DELISTED
Epizyme, Inc
EPZM
$632K 0.94%
50,378
– –
CRSP icon
30
CRISPR Therapeutics
CRSP
$5.74B
$622K 0.92%
13,214
– –
ARNA
31
DELISTED
Arena Pharmaceuticals Inc
ARNA
$573K 0.85%
9,770
– –
CELG
32
DELISTED
Celgene Corp
CELG
$520K 0.77%
5,625
-2,885
-34% -$274K
MGNX icon
33
MacroGenics
MGNX
$260M
$510K 0.75%
30,075
– –
GBT
34
DELISTED
Global Blood Therapeutics, Inc.
GBT
$499K 0.74%
9,479
– –
PCRX icon
35
Pacira BioSciences
PCRX
$1.03B
$489K 0.72%
11,250
– –
BHVN
36
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$475K 0.7%
10,852
– –
ICPT
37
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$467K 0.69%
5,872
+116
+2% +$10.4K
NTLA icon
38
Intellia Therapeutics
NTLA
$1.84B
$466K 0.69%
28,490
– –
ZGNX
39
DELISTED
Zogenix, Inc.
ZGNX
$465K 0.69%
9,725
– –
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$458K 0.68%
36,731
– –
NKTR icon
41
Nektar Therapeutics
NKTR
$2.55B
$445K 0.66%
834
+147
+21% +$73.7K
DCPH
42
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$420K 0.62%
18,631
– –
VKTX icon
43
Viking Therapeutics
VKTX
$3.95B
$402K 0.59%
48,485
– –
MDGL icon
44
Madrigal Pharmaceuticals
MDGL
$12.6B
$374K 0.55%
3,570
– –
FBIO icon
45
Fortress Biotech
FBIO
$93.4M
$351K 0.52%
15,602
– –
ANAB icon
46
AnaptysBio
ANAB
$1.7B
$345K 0.51%
6,116
– –
CKPT
47
DELISTED
Checkpoint Therapeutics
CKPT
$342K 0.51%
11,276
– –
AMRN
48
Amarin Corp
AMRN
$297M
$323K 0.48%
832
– –
TECH icon
49
Bio-Techne
TECH
$11.4B
$323K 0.48%
6,204
– –
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$2.59B
$322K 0.48%
5,064
– –
1
2
3 4

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2019 Portfolio in Review

As of Q2 2019, Opus Point Partners Management held 76 positions worth $67.6M, down 8.4% from $73.8M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Opus Point Partners Management withdrew a net $3.41M in Q2 2019, closing 13 positions and reducing 1 holding. Its most notable exit was Regenxbio, an estimated $506K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 60% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in Biogen worth $263K.

  • Opus Point Partners Management's largest Q2 2019 buy was Biogen: 1,123 shares worth $263K.
  • Opus Point Partners Management added most to Sarepta Therapeutics in Q2 2019, an estimated $255K increase.
  • Opus Point Partners Management's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $274K.
  • Opus Point Partners Management fully exited Regenxbio in Q2 2019, selling an estimated $506K.
  • Opus Point Partners Management's ten largest holdings make up 58% of its $67.6M portfolio in Q2 2019.
  • Opus Point Partners Management opened 1 new position and closed 13 in Q2 2019.
  • Opus Point Partners Management's portfolio value fell 8.4% quarter-over-quarter to $67.6M.

Based on Opus Point Partners Management's 13F filing for Q2 2019, filed 14 Aug 2019.